口服磷酰阿糖胞苷联合粒细胞集落刺激因子治疗急性髓系白血病和骨髓增生异常综合征
Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor.
作者信息
Okumura H, Yoshida T, Takamatsu H, Katoh T, Murashima M, Watanabe A, Yamauchi H, Matano S, Chuhjo T, Takeshima M, Kaya H, Ohtake S, Nakamura S, Matsuda T
机构信息
Department of Internal Medicine, Toyama Prefectural Central Hospital, Japan.
出版信息
Int J Hematol. 1997 Apr;65(3):263-8. doi: 10.1016/s0925-5710(96)00572-5.
Cytarabine ocfosfate (SPAC) was administered orally to 19 patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). SPAC was administered at doses of 200-300 mg/day for more than 14 days with granulocyte colony-stimulating factor (G-CSF). Four of the 12 patients with AML and 1 of the 7 patients with MDS achieved complete remission (CR) after one cycle of SPAC treatment. Especially, 3 of the 6 patients with newly diagnosed AML achieved CR. Major side effects of SPAC were myelosuppression and tolerable gastrointestinal disorders. The treatment with SPAC is a therapeutic option in elderly patients or patients with organ failure.
口服磷酰阿糖胞苷（SPAC）对19例急性髓系白血病（AML）和骨髓增生异常综合征（MDS）患者进行了治疗。SPAC以200 - 300mg/天的剂量给药，持续超过14天，并联合粒细胞集落刺激因子（G-CSF）。12例AML患者中有4例，7例MDS患者中有1例在一个周期的SPAC治疗后实现完全缓解（CR）。特别是，6例新诊断的AML患者中有3例实现了CR。SPAC的主要副作用是骨髓抑制和可耐受的胃肠道紊乱。SPAC治疗是老年患者或器官功能衰竭患者的一种治疗选择。
Zotero 插件